恆星科技(002132.SZ):擬以1.39億元對恆星化學增資 以加快投建年產12萬噸高性能有機硅聚合物項目
格隆匯6月7日丨恆星科技(002132.SZ)公佈,公司於2021年6月6日召開第六屆董事會第十九次會議,審議通過了《關於對控股子公司增資的議案》。公司擬以人民幣1.39億元對公司控股子公司內蒙古恆星化學有限公司(“恆星化學”)增資,以加快投資建設“內蒙古恆星化學有限公司年產12萬噸高性能有機硅聚合物項目”。同日,公司與恆星化學其他股東簽訂了內蒙古恆星化學有限公司《增資擴股協議書》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.